ERBB2 and glioblastoma: Another phase-I trial (NCT03383978) is evaluating the safety and tolerability of HER2-targeted NK-92 cells in combination with the immune checkpoint inhibitor ezabenlimab in patients with recurrent HER2-positive glioblastoma.